Treatment interruptions and discontinuations among patients with stage III unresectable non–small cell lung cancer treated with durvalumab at the Veterans Health Administration

MLA

Munaf Alkadimi, et al. “Treatment Interruptions and Discontinuations among Patients with Stage III Unresectable Non–small Cell Lung Cancer Treated with Durvalumab at the Veterans Health Administration.” Journal of Clinical Oncology, vol. 40, June 2022, p. 8554. EBSCOhost, https://doi.org/10.1200/jco.2022.40.16_suppl.8554.

APA

Munaf Alkadimi, Amanda Moore, Christopher R Frei, Kelly R Reveles, Lance Brannman, Ion Cotarla, Andrew Frankart, Tiernan Mulrooney, Paromita Datta, Jennifer Whitehead, Kathleen Franklin, Renee Reichelderfer, Madison H. Williams, Ryan A. Williams, Sarah Allison Smith, Xavier Jones, & Zohra Nooruddin. (2022). Treatment interruptions and discontinuations among patients with stage III unresectable non–small cell lung cancer treated with durvalumab at the Veterans Health Administration. Journal of Clinical Oncology, 40, 8554. https://doi.org/10.1200/jco.2022.40.16_suppl.8554

Chicago

Munaf Alkadimi, Amanda Moore, Christopher R Frei, Kelly R Reveles, Lance Brannman, Ion Cotarla, Andrew Frankart, et al. 2022. “Treatment Interruptions and Discontinuations among Patients with Stage III Unresectable Non–small Cell Lung Cancer Treated with Durvalumab at the Veterans Health Administration.” Journal of Clinical Oncology 40 (June): 8554. doi:10.1200/jco.2022.40.16_suppl.8554.